Minakem-flap
Minakem-flap

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: UPPTHERA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 28, 2021

            Details:

            HitGen has entered into a drug discovery research collaboration with UPPTHERA Inc. to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase. Identified compounds will be exclusively licensed to UPPTHERA for further development.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Undisclosed

            Partner/Sponsor/Collaborator: H.C. Wainwright & Co

            Deal Size: $17.6 million Upfront Cash: Undisclosed

            Deal Type: Private Placement February 23, 2021

            Details:

            The Company intends to use up to approximately $5.88 million of the net proceeds to repay certain indebtedness and the remainder of the net proceeds for general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Sky9 Capital

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing February 18, 2021

            Details:

            The funds will be mainly used to enhance its artificial intelligence (AI)-driven novel drug R&D platform, accelerate the preclinical development of several new medicine pipelines and expand international business cooperation.